comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 15:59:02 - browse：8521

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

WSS

The history of OxyContin, told through Purdue Pharma documents

See how much Covid

ASCO: AstraZeneca says CAR

Faced with fears of OxyContin misuse, sales reps touted its safety

Target recalls 2.2 million additional candles due to laceration, burn hazards

Faced with fears of OxyContin misuse, sales reps touted its safety

leisure time

comprehensive

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

See how much Covid

Wildfire smoke exposes gaps in outdoor worker protections

Who are the detained American citizens released from prison in Iran?

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Drug repurposing or repositioning? The language matters

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Sports medicine is finally prioritizing gender equality

How to increase colonoscopy rates? Looks like an AI can help

focus

At ASCO, AstraZeneca reports strong data for breast cancer drug

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

FDA's Pazdur wants cancer trials to range beyond China alone

Faced with fears of OxyContin misuse, sales reps touted its safety

Ionis drug prevents swelling attacks due to hereditary angioedema

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

hotspot

entertainment

hotspot

explore